World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
30828
World Ranking
15456
National Ranking
7796

Overview

Myron S. Czuczman is affiliated with Citius Pharmaceuticals, Inc. in the United States. Their research primarily focuses on oncology, with a total of 29 publications in the field of medicine. Within oncology, key subfields of study include pathology and forensic medicine, genetics, immunology, and dermatology.

The scientist's work covers several main topics, including:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Cutaneous lymphoproliferative disorders research
  • Toxin Mechanisms and Immunotoxins
  • Cancer Immunotherapy and Biomarkers
  • Viral-associated cancers and disorders

Recent publications authored or co-authored by Myron S. Czuczman include:

  • ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma, 2021, Journal of Clinical Oncology
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy, 2020, The American Journal of Surgical Pathology
  • Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302, 2022, Blood
  • Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma, 2024, Journal of Clinical Oncology
  • Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models, 2023, Frontiers in Immunology

Publication venues frequently associated with Myron S. Czuczman's work include:

  • Blood
  • Journal of Clinical Oncology
  • Frontiers in Immunology
  • The American Journal of Surgical Pathology
  • Cancer Reports

Frequent co-authors collaborating with Myron S. Czuczman are:

  • Chean Eng Ooi
  • Dongyuan Xing
  • Nicholas Sauter
  • Preeti Singh
  • Thomas E. Witzig

Best Publications

  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    P McLaughlin;A J Grillo-López;B K Link;R Levy

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

    Myron S. Czuczman;A. J. Grillo-López;C. A. White;M. Saleh

  • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    Wyndham H Wilson;Owen A O'Connor;Myron S Czuczman;Ann S LaCasce

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides

  • Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

    Thomas A. Davis;Antonio J. Grillo-López;Christine A. White;Peter McLaughlin

  • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

    Kieron Dunleavy;Stefania Pittaluga;Myron S. Czuczman;Sandeep S. Dave

  • Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

    N. L. Berinstein;A. J. Grillo-Lopez;C. A. White;I. Bence-Bruckler

  • Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

    J. M. Vose;B. K. Link;M. L. Grossbard;M. Czuczman

  • Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

    L. D. Piro;C. A. White;A. J. Grillo-López;N. Janakiraman

  • Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

    Asher Chanan-Khan;Kena C. Miller;Laurie Musial;David Lawrence

  • Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.

    Myron S. Czuczman;Robin Weaver;Baha Alkuzweny;Judy Berlfein

  • An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

    T. E. Witzig;Julie Marie Vose;P. L. Zinzani;C. B. Reeder

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Use of rituximab, the new FDA-approved antibody

    Gail A. Leget;Myron S. Czuczman

  • Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    Maria Corinna A Palanca-Wessels;Myron Czuczman;Gilles Salles;Sarit Assouline

  • Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

    Thomas A. Davis;Christine A. White;Peter McLaughlin;Myron S. Czuczman

Frequent Co-Authors

Leo I. Gordon
Leo I. Gordon Northwestern University
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
John P. Leonard
John P. Leonard Cornell University
Thomas E. Witzig
Thomas E. Witzig Mayo Clinic
Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Bruce D. Cheson
Bruce D. Cheson Georgetown University
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Oliver W. Press
Oliver W. Press University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in a medical career but aren’t ready to commit to a full MD program, there are valuable alternatives worth exploring. Aspiring nurses might consider adn programs, which offer a quicker path to becoming a registered nurse and are often more accessible in terms of admissions requirements.

For those interested in the administrative side of healthcare, pursuing a health care administration degree online can open doors to management roles in hospitals, clinics, and healthcare organizations—often with flexible, accelerated learning formats.

Entry requirements vary across fields. Prospective Licensed Practical Nurses (LPNs) may wonder, do I need to take the teas test for lpn? The answer depends on the program, with some schools waiving standardized test requirements.

Finally, support roles like medical coding are in high demand. You can start this career by taking online medical coding classes with financial aid, making it accessible to students from various backgrounds.

Best Scientists Citing Myron S. Czuczman

Trending Scientists